MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/cancers13215563

Медицинская библиотека · Cancers · 2021

ADAM17-A Potential Blood-Based Biomarker for Detection of Early-Stage Ovarian Cancer.

Rogmans Christoph, Kuhlmann Jan Dominik, Hugendieck Gerrit, Link Theresa, Arnold Norbert, Weimer Jörg Paul, Flörkemeier Inken, Rambow Anna-Christina, Lieb Wolfgang, Maass Nicolai, Bauerschlag Dirk O, Hedemann Nina

СтатьяПеревод в очереди

Аннотация

Ovarian cancer has the highest mortality rate among gynecological tumors. This is based on late diagnosis and the lack of early symptoms. To improve early detection, it is essential to find reliable biomarkers. The metalloprotease ADAM17 could be a potential marker, as it is highly expressed in many solid tumors, including ovarian and breast cancer. The aim of this work is to evaluate the relevance of ADAM17 as a potential diagnostic blood-based biomarker in ovarian cancer. Ovarian cancer cell lines IGROV-1 and A2780, as well as primary patient-derived tumor cells obtained from tumor tissue and ascitic fluid, were cultured to analyze ADAM17 abundance in the culture supernatant. In a translational approach, a cohort of 117 well-characterized ovarian cancer patients was assembled and ADAM17 levels in serum and corresponding ascitic fluid were determined at primary diagnosis. ADAM17 was quantified by enzyme-linked immunosorbent assay (ELISA). In the present study, ADAM17 was detected in the culture supernatant of ovarian cancer cell lines and primary cells. In addition, ADAM17 was found in serum and ascites of ovarian cancer patients. ADAM17 level was significantly increased in ovarian cancer patients compared to an age-matched control group (p < 0.0001). Importantly early FIGO I/II stages, which would not have been detected by CA-125, were associated with higher ADAM17 concentrations (p = 0.007). This is the first study proposing ADAM17 as a serum tumor marker in the setting of a gynecological tumor disease. Usage of ADAM17 in combination with CA-125 and other markers could help detect early stages of ovarian cancer.

Для цитирования: Rogmans Christoph, Kuhlmann Jan Dominik, Hugendieck Gerrit, Link Theresa, Arnold Norbert, Weimer Jörg Paul, Flörkemeier Inken, Rambow Anna-Christina, Lieb Wolfgang, Maass Nicolai, Bauerschlag Dirk O, Hedemann Nina. ADAM17-A Potential Blood-Based Biomarker for Detection of Early-Stage Ovarian Cancer.. Cancers. 2021. DOI: 10.3390/cancers13215563.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.